Mankind, Cancer, Innovent, India, Pharma, Sintilimab, Market, Across, Innovative, Patients, Biologics, Immunotherapy, Patient, Will, More, Products, Company, Care, Partnership, Indian,
Mankind Pharma and Innovent Biologics Partner to Revolutionize Cancer Care in India with Innovative Immunotherapy Sintilimab
Mumbai, India: December 26, 2024 - Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND) and Innovent Biologics have announced a groundbreaking partnership to exclusively license and commercialize sintilimab, an advanced PD-1 immunotherapy, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.
Cancer has become a major health concern in India, with its burden projected to reach 29.8 million DALYs by 2025, according to The National Cancer Registry Programme1. In response to this pressing challenge, the partnership between Mankind Pharma and Innovent Biologics offers a pivotal solution, aiming to tackle the rising incidence of cancer and improve patient outcomes across the country.
Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is a high-quality PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly. Its mechanism of blocking the PD-1/PD-L1 pathway reactivates T-cells, enhancing the body's natural ability to target and eliminate cancer cells[i]. The drug has demonstrated remarkable efficacy and favorable safety across multiple major cancer types with eight approved indications in China, including non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma. TYVYT® (sintilimab injection), is one of the top therapy choices in immunotherapy, has already benefited millions of cancer patients since its launch in 2018. This versatile immunotherapy holds the potential to make a significant impact for oncology patients in India.
Under the agreement, Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India. Innovent will oversee manufacturing and supply of the product, ensuring consistent availability and adherence to high-quality standards. Innovent will be eligible to receive upfront, regulatory and commercial milestone payments.
"Mankind Pharma is excited to partner exclusively with Innovent Biologics to launch sintilimab in India. This groundbreaking immunotherapy represents a significant advancement in cancer treatment, offering new hope for patients battling a range of cancers. By bringing this innovative therapy to the Indian market, we are committed to improving patient outcomes and reinforcing our position as a leader in oncology. Mankind Pharma brings its extensive pharmaceutical expertise and expansive distribution network to this partnership, with a robust field force of 16,000+ personnel and over 13,000 stockists across India. This ecosystem will be crucial in ensuring widespread access to sintilimab across urban and rural markets. The partnership represents more than a commercial agreement – it's a commitment to transforming oncological care in India, making innovative treatments available to a broader patient population," shared Mr Atish Majumdar – Sr President – Sales & Marketing, Mankind Pharma Limited.
Dr. Samuel Zhang, Chief Business Officer of Innovent Biologics, stated: “Innovent is delighted to partner with Mankind Pharma to introduce our innovative PD-1 inhibitor sintilimab in India, providing new hope for patients battling various forms of cancer. Leveraging Mankind Pharma’s extensive network and deep expertise, we are confident that sintilimab will be rapidly accessible to patients across the country. Together, we are committed to advancing patient care in India by making cutting-edge treatments more accessible and affordable.”
About Mankind Pharma
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical companies in India, which focuses on the domestic market with its Pan India presence. In a strategic move to strengthen its position in the Indian women's health and fertility drug market, Mankind Pharma recently acquired Bharat Serums and Vaccines. This acquisition enhances Mankind's portfolio and market reach in super speciality and high barriers to entry segments with BSVs highly capable product development capabilities. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including cardiovascular, antidiabetic, anti-infectives, gastrointestinal, neuro/CNS, oncology, respiratory, among others with a strategy to increase chronic presence going ahead. The company has transferred its Over-the-Counter (OTC) business undertaking to its wholly owned subsidiary, Mankind Consumer Products Private Limited (MCPPL). Mankind Pharma’s consumer products portfolio includes several category-leading brands that include Manforce, HealthOK, Prega News, AcneStar, Unwanted and Gas-O-Fast across categories such as wellness, hygiene and personal care products.
The company has 30 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 660 scientists.
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 13 products in the market. It has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.
Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
✍ Share Your Knowledge with Our Community!
get rewards for paying bills
upto ₹250 off when you pay your first bill on CRED